Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hemoglobin D

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,043 result(s) found for: Hemoglobin D. Displaying page 1 of 53.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-004209-15 Sponsor Protocol Number: GBT440-007 Start Date*: 2019-01-08
    Sponsor Name:Global Blood Therapeutics, Inc.
    Full Title: A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants with Sickle Cell Disease
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-000075-16 Sponsor Protocol Number: BAY88-8223/16216 Start Date*: 2012-06-20
    Sponsor Name:Bayer HealthCare AG
    Full Title: Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastasis
    Medical condition: Castrate Resistant Prostate Cancer/Hormone-Refractory Prostate Cancer patients with bone metastasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10036916 Prostate cancer stage D LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DE (Completed) NO (Completed) FI (Completed) BE (Completed) ES (Completed) CZ (Completed) IE (Completed) GB (Completed) IT (Completed) DK (Prematurely Ended) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002887-25 Sponsor Protocol Number: 2601 Start Date*: 2006-06-27
    Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE
    Full Title: Bevacizumab+folfiri in untreated patients with advanced colorectal cancer. A phase II multicenter study of the Gruppo Oncologico dell'Italia Meridionale. (GOIM).
    Medical condition: untreated patients with advanced colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010035 Colorectal cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005889-40 Sponsor Protocol Number: ABR-15108 Start Date*: 2007-08-14
    Sponsor Name:Academic Medical Centre
    Full Title: N-Acetylcysteine for Treatment of Sickle Cell Disease
    Medical condition: Patients homozygous for sickle cell disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040644 Sickle cell disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005480-28 Sponsor Protocol Number: IJG-FER-2012 Start Date*: 2013-05-21
    Sponsor Name:Institut d?Investigació en Atenció Primaria IDIAP Jordi Gol
    Full Title: Effectiveness of adaptation of the dose of iron supplementation in pregnancy on maternal-child health. Randomized clinical trial (ECLIPSES)
    Medical condition: Pregnant women, less than 12 week of gestations,without anemia (Hb <110 d / dL) in the pre-analytical at 12 weeks
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000039-33 Sponsor Protocol Number: 2018-06-017 Start Date*: Information not available in EudraCT
    Sponsor Name:Groupement de Coopération Sanitaire Ramsay Générale de Santé pour l’Enseignement et la Recherche
    Full Title: Multicentric, double-blind, randomized study to show that the addition of IV tranexamic acid versus placebo in ACL ligamentoplasties leads to a decrease in blood loss and postoperative pain
    Medical condition: Patients undergoing primary ACL ligamentoplasty with hamstring tendon removal on an outpatient basis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000609-36 Sponsor Protocol Number: FIFERM03 Start Date*: 2019-12-16
    Sponsor Name:Hospital Vall d´Hebrón
    Full Title: Study of the use of Liposomal Iron in the treatment of iron deficiency anemia in pregnancy and puerperium
    Medical condition: Iron deficiency anemia
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004203-41 Sponsor Protocol Number: 54767414MMY2040 Start Date*: 2018-04-26
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-004627-12 Sponsor Protocol Number: CABASEM-SOGUG Start Date*: 2011-12-22
    Sponsor Name:SOGUG - Spanish Oncology Genitourinary Group
    Full Title: Phase II Study of Weekly Cabazitaxel for Advanced Prostate Cancer in "Unfit" Hormone-Refractory Patients Previously Treated with Docetaxel.
    Medical condition: Advanced Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036920 Prostate cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-004592-23 Sponsor Protocol Number: DLIFE Start Date*: 2015-03-12
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Phase IV randomized, double blind, placebo-controlled study: role of hypovitaminosis D in heart failure and possible advantages of cholecalciferol (Vit D) administration
    Medical condition: HEART FAILURE
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10011949 Decompensation cardiac LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003438-18 Sponsor Protocol Number: AG-348inSCD Start Date*: 2020-05-14
    Sponsor Name:Julius Clinical
    Full Title: Evaluation of safety and efficacy in mitapivat sulfate in adult patients with sickle cell disease
    Medical condition: Sickle cell disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022162-27 Sponsor Protocol Number: AIO0209 Start Date*: 2011-06-07
    Sponsor Name:Martin-Luther-Universität Halle-Wittenberg
    Full Title: FOLFOX/bevacizumab with or without irinotecan in first-line treatment for metastatic colorectal cancer. A randomized phase II study.
    Medical condition: Unresectable stage IV (UICC) colorectal cancer (primary tumor may be present)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002992-16 Sponsor Protocol Number: EMN17/54767414MMY3014 Start Date*: 2019-01-30
    Sponsor Name:European Myeloma Network (EMN)
    Full Title: A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) GR (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002162-21 Sponsor Protocol Number: JECF-VITD-2011-01 Start Date*: 2012-04-24
    Sponsor Name:José Esteban Castelao Fernández
    Full Title: A phase II randomized, prospective, multicenter, placebo-controlled clinical trial to evaluate the chemopreventive effect of vitamin D in women at high risk of breast cancer.
    Medical condition: Women at high risk of developing breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001746-10 Sponsor Protocol Number: CSEG101A2301 Start Date*: 2019-07-08
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/ Hydroxycarbamide Therapy, in Adole...
    Medical condition: Sickle Cell Disease with vaso-occlusive crisis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    20.1 10010331 - Congenital, familial and genetic disorders 10002077 Anaemia sickle cell LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) GR (Completed) DE (Completed) FI (Trial now transitioned) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000254-64 Sponsor Protocol Number: 114056 Start Date*: 2012-04-12
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open, controlled study to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals’ 10- valent pneumococcal conjugate vaccine administered to children with sickle cell...
    Medical condition: Active immunization against disease caused by Streptococcus pneumoniae in children from 8 weeks up to 2 years of age.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10061190 Haemophilus infection PT
    17.1 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-000225-30 Sponsor Protocol Number: DMA-Clin-199-2013-001 Start Date*: 2013-04-12
    Sponsor Name:DiaMedica USA Inc.
    Full Title: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, SINGLE DOSE AND MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PROOF OF CONCEPT OF DM-199 IN HEALTHY SUBJECTS...
    Medical condition: Diabetes Mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    16.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003251-11 Sponsor Protocol Number: DIABGAD-1 Start Date*: 2012-11-21
    Sponsor Name:Linköping university
    Full Title: Pilot Trial to preserve residual insulin secretion in children and adolescents with recent onset Type 1 diabetes by using GAD-antigen (Diamyd) therapy in combination with Vitamin D and Ibuprofen .
    Medical condition: Type 1 diabetes in children and adolescents
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004552-37 Sponsor Protocol Number: 18CH052 Start Date*: 2019-05-07
    Sponsor Name:CHU SAINT-ETIENNE
    Full Title: Dose Study of Tranexamic Acid in Total Hip Replacement to Reduce Postoperative Hemoglobin Loss. A Phase 2 Randomized Double-blind Monocentric Study
    Medical condition: Arthropathy of Hip
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10077058 Hip arthropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004214-41 Sponsor Protocol Number: LSO-OL006 Start Date*: 2007-04-19
    Sponsor Name:Light Science Oncology Inc.
    Full Title: A Multicenter Multinational Phase 3 Randomized Study to Evaluate the Safety and Efficacy of Treating Colorectal Cancer Patients with Recurrent Liver Metastases using the LitxTM System plus Chemothe...
    Medical condition: Patients with recurrent liver metastases from colorectal cancer who have progressed on either FOLFOX4 or FOLFIRI
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050035 Metastatic colon cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) LV (Completed) IT (Completed) DE (Completed) AT (Completed) SE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 15:55:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA